Fox Chase Cancer Center to Hold Fourth Annual Cancer Epigenetics Symposium

Dr. Whetstine
Fox Chase Cancer Center’s Cancer Epigenetics Institute will hold its fourth annual free hybrid Cancer Epigenetics Symposium at the Franklin Institute in Philadelphia on Thursday, March 7.

PHILADELPHIA (March 1, 2024) — Fox Chase Cancer Center’s Cancer Epigenetics Institute will hold its fourth annual free hybrid Cancer Epigenetics Symposium at the Franklin Institute in Philadelphia on Thursday, March 7. The annual event brings research leaders together to explore the latest discoveries that will assist in bringing epigenetics from the lab to patients.

A major goal of this annual international symposium is to bring world-class science to a global audience at any educational level. There are already more than 600 registered attendees from 19 countries.

“We are fortunate to have leaders in academia, pharma, and biotech come together to tell anyone, anywhere about their newest discoveries. These findings cover fundamental scientific discovery as well as the potential clinical impact of therapies targeting epigenetics and nuclear function,” said Johnathan Whetstine, PhD, Director of the Cancer Epigenetics Institute.

This year’s symposium, “From Gene Regulation to 3D Genomes to Development & Therapeutics,” will feature presentations from world leaders in academia and industry. Participating institutions include Howard Hughes Medical Institute, Institut Curie, Fred Hutch Cancer Center, Stanford University, Columbia University, Memorial Sloan Kettering Cancer Center, Boston Children’s Hospital, Harvard Medical School, the University of Massachusetts, and Ludwig Maximilian University of Munich. Seven pharma and biotech leaders, including Daiichi Sankyo and AstraZeneca, will also participate.

The symposium keynote will be delivered by Genevieve Almouzni, PhD, of the Research Center of the Institut Curie, and Steven Henikoff, PhD, of the Fred Hutchinson Cancer Center and Howard Hughes Medical Institute. Along with these key speakers, the next generation of trainees who have received the C. David Allis Travel Awards will present their research.

“This day features those that are leading the world, while featuring those that will be creating the next series of discoveries in the years ahead. I enjoy seeing the trainees present in this forum and seeing their smiles as they receive the Cancer Epigenetics Institute travel awards or poster prizes for their scientific discoveries,” said Whetstine.

The meeting will also include a poster session for in-person attendees and two translational speaker sessions with pharma/biotech leaders who are developing the next generation of epigenetic technologies and therapies.

The program will run from 8:30 a.m. to 5:30 p.m. and will be followed by a reception from 5:30 to 7 p.m. Due to a record-breaking number of attendees, the event has reached venue capacity and in-person registration is now closed. However, the event can still be attended virtually.

Click here for more information on the symposium.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427